KVACW — Keen Vision Acquisition Corp.
—
Nasdaq ·
Financials ·
Diversified Financial Services ·
CIK 1889983 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -232,844 | 92,087 | 13,258,032 | 9,098 | 7,467,809 |
| Dec 2025 | 0 | — | -131,656 | 410,571 | 57,039,871 | 11,206 | 7,047,398 |
| Sep 2025 | 0 | — | -248,480 | 373,466 | 56,045,539 | 15,880 | 6,463,637 |
| Jun 2025 | 0 | — | -192,040 | 558,055 | 73,127,796 | 1,317 | 5,827,617 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-784,137
Investing CF
$16,023,721
Financing CF
$-15,282,926
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
—
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-7,011,084
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-743,509
Pretax Income TTM
$1,910,263
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -743,509 | 1,910,263 | 57,039,871 | 7,047,398 | — | -784,137 |
| Dec 2024 | 0 | -1,460,753 | 7,409,180 | 70,436,851 | 4,262,898 | — | -1,142,290 |
| Dec 2023 | 0 | -478,676 | 1,454,758 | 155,688,933 | 3,004,000 | — | -705,903 |
| Dec 2022 | 0 | -697 | -693 | 194,807 | 173,573 | — | -3,291 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HASI | HA Sustainable Infrastructure Capital, Inc. | $5.27B | $41.21 | — |
| DMII | Drugs Made In America Acquisition II Corp. | $641.46M | $10.07 | — |
| INV | Innventure, Inc. | $536.21M | $6.38 | — |
| BCSS | Bain Capital GSS Investment Corp. | $478.38M | $10.20 | — |
| EVAC | EQV Ventures Acquisition Corp. II | $477.46M | $10.17 | — |
News headlines (Yahoo Finance, 1h cache)
Medera and University of Kansas Medical Center Announce First Patient Treated in Pioneering Gene Therapy Trial for Duchenne Muscular Dystrophy Associated Cardiomyopathy
2025-07-15 12:00 · Yahoo
Medera’s Novoheart Enters New Collaboration to Develop Human Mini-Heart Models Aimed at Transforming Treatment for Hypoplastic Left Heart Syndrome
2025-06-24 12:00 · Yahoo
Medera and Novoheart Presented Breakthroughs in Human mini-Heart Platforms and Gene Therapy at ISSCR 2025
2025-06-13 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.